Search results for " Humans"

showing 10 items of 2466 documents

Small Bowel Carcinomas in Coeliac or Crohn’s Disease: Clinico-pathological, Molecular, and Prognostic Features. A Study From the Small Bowel Cancer I…

2017

Background and aims An increased risk of small bowel carcinoma [SBC] has been reported in coeliac disease [CD] and Crohn's disease [CrD]. We explored clinico-pathological, molecular, and prognostic features of CD-associated SBC [CD-SBC] and CrD-associated SBC [CrD-SBC] in comparison with sporadic SBC [spo-SBC]. Methods A total of 76 patients undergoing surgical resection for non-familial SBC [26 CD-SBC, 25 CrD-SBC, 25 spo-SBC] were retrospectively enrolled to investigate patients' survival and histological and molecular features including microsatellite instability [MSI] and KRAS/NRAS, BRAF, PIK3CA, TP53, HER2 gene alterations. Results CD-SBC showed a significantly better sex-, age-, and st…

Male0301 basic medicineNeuroblastoma RAS viral oncogene homologOncologySurvivalReceptor ErbB-2Colorectal cancermedicine.disease_causeInflammatory bowel diseaseInflammatory bowel diseasetumour-infiltrating lymphocyteErbB-20302 clinical medicineCrohn DiseaseRetrospective StudieRisk Factors80 and overChildClass I Phosphatidylinositol 3-KinaseAged 80 and overColonic NeoplasmSettore MED/12 - GastroenterologiaCrohn's diseaseMLH1 methylationTumour-infiltrating lymphocytesGastroenterologyGeneral MedicineMiddle AgedPrognosisInflammatory bowel disease; Microsatellite instability; MLH1 promoter methylation; Survival; Tumour-infiltrating lymphocytes; Gastroenterology030220 oncology & carcinogenesisColonic NeoplasmsSurvival AnalysiKRASHumanReceptorAdultProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognosiClass I Phosphatidylinositol 3-KinasesSettore MED/08 - Anatomia PatologicaNOProto-Oncogene Proteins p21(ras)MLH1 promoter methylationYoung Adult03 medical and health sciencesInternal medicinemedicineCarcinomaHumansMLH1 methylation; inflammatory bowel disease; microsatellite instability; survival; tumour-infiltrating lymphocytesneoplasmsAgedRetrospective StudiesInflammatory bowel disease; Microsatellite instability; MLH1 promoter methylation; Survival; Tumour-infiltrating lymphocytes; Adult; Aged; Aged 80 and over; Celiac Disease; Child; Class I Phosphatidylinositol 3-Kinases; Colonic Neoplasms; Crohn Disease; Humans; Male; Microsatellite Instability; Middle Aged; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Receptor ErbB-2; Retrospective Studies; Risk Factors; Survival Analysis; Tumor Suppressor Protein p53; Young Adult; Gastroenterologybusiness.industryTumour-infiltrating lymphocyteRisk FactorCancerMicrosatellite instabilityinflammatory bowel disease; microsatellite instability; MLH1 promoter methylation; tumour-infiltrating lymphocytes; survivalmedicine.diseaseSurvival Analysiseye diseasesdigestive system diseasesCeliac Disease030104 developmental biologyMicrosatellite instabilityTumor Suppressor Protein p53businessJournal of Crohn's and Colitis
researchProduct

Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

2017

Background: Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time trends in incidence and survival, and provide information about centralisation of treatments in seven European countries. Methods: We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was calcu…

Male0301 basic medicinePathologypopulation-based registriesCancer Care Facilities; Delivery of Health Care; Europe; Female; Hospitalization; Humans; Incidence; Male; Neoplasms; Rare Diseases; Registries; Survival Rate; Oncology0302 clinical medicineNeoplasmsMedicineRegistriesmedia_commonTumors -- Treatment -- Europeeducation.field_of_studyRelative survivalIncidenceIncidence (epidemiology)RARECARE projectEuropeHospitalizationSurvival RateOncology030220 oncology & carcinogenesis/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_beingFemalemedicine.medical_specialtyHealth surveysPopulationSocio-culturaleCancer Care Facilities03 medical and health sciencesRare DiseasesSDG 3 - Good Health and Well-beingHumansmedia_common.cataloged_instanceCancer -- MortalityRisk factorEuropean unioneducationSurvival rateOncology cancer burden incidence rare cancerpopulation-based registriesrare cancers cancer registry RARECAREbusiness.industryRare cancerCancer -- Patients -- Long-term careCancer registry030104 developmental biologycancer burdenbusinessDelivery of Health CareDemographyRare disease
researchProduct

Has VZV epidemiology changed in Italy? Results of a seroprevalence study

2017

The aim of the study was to evaluate if and how varicella prevalence has changed in Italy. In particular a seroprevalence study was performed, comparing it to similar surveys conducted in pre-immunization era. During 2013–2014, sera obtained from blood samples taken for diagnostic purposes or routine investigations were collected in collaboration with at least one laboratory/center for each region, following the approval of the Ethics Committee. Data were stratified by sex and age. All samples were processed in a national reference laboratory by an immunoassay with high sensitivity and specificity. Statutory notifications, national hospital discharge database and mortality data related to V…

Male0301 basic medicinePediatricsCross-sectional studySeroprevalenceSettore MED/42 - Igiene Generale E ApplicataAntibodies Viralmedicine.disease_causeChickenpox0302 clinical medicineChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Adolescent; Adult; Age Factors; Aged; Aged 80 and over; Antibodies Viral; Chickenpox; Child; Child Preschool; Cross-Sectional Studies; Female; Humans; Infant; Infant Newborn; Italy; Male; Middle Aged; Seroepidemiologic Studies; Young Adult; Immunology and Allergy; Immunology; PharmacologySeroepidemiologic StudiesEpidemiology80 and overImmunology and AllergyAge FactorViral030212 general & internal medicineYoung adultChildskin and connective tissue diseasesAged 80 and overSurveillanceChickenpoxVaricella-Zoster ViruAge FactorsMiddle AgedResearch PapersItalyChild PreschoolFemaleChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster Virus; Immunology and Allergy; Immunology; PharmacologyHumanAdultmedicine.medical_specialtyAdolescent030106 microbiologyImmunologyAntibodiesNOYoung Adult03 medical and health sciencesChickenpox; Immunization; Seroprevalence; Surveillance; Varicella-Zoster VirusmedicineHumansSeroprevalencePreschoolAgedCross-Sectional StudiePharmacologybusiness.industrySeroepidemiologic StudieInfant NewbornVaricella zoster virusInfantSeroepidemiologic StudiesNewbornmedicine.diseaseVaricella-Zoster VirusCross-Sectional StudiesImmunizationImmunizationsense organsChickenpox Immunization Seroprevalence Surveillance Varicella-Zoster Virus Immunology and Allergy Immunology Pharmacologybusiness
researchProduct

Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

2020

Abstract Background High uptake of antiretroviral treatment (ART) is essential to reduce human immunodeficiency virus (HIV) transmission and related mortality; however, gaps in care exist. We aimed to construct the continuum of HIV care (CoC) in 2016 in 11 European Union (EU) countries, overall and by key population and sex. To estimate progress toward the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 target, we compared 2016 to 2013 estimates for the same countries, representing 73% of the population in the region. Methods A CoC with the following 4 stages was constructed: number of people living with HIV (PLHIV); proportion of PLHIV diagnosed; proportion of those diagnosed …

Male0301 basic medicinePsychological interventionHuman immunodeficiency virus (HIV)MedizinContinuum of care; Europe; HIV infection; Key population; Sex; Anti-Retroviral Agents; Continuity of Patient Care; European Union; HIV; Humans; Male; HIV InfectionsHIV InfectionsContinuum of care; Europe; HIV infection; Key population; Sexmedicine.disease_causekey population0302 clinical medicineContinuum of careHIV Infection030212 general & internal medicineMen having sex with menContinuum of caremedia_commoneducation.field_of_study[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyTransmission (medicine)Continuity of Patient CareEuropeInfectious DiseasesAcademicSubjects/MED00290Anti-Retroviral AgentsHIV infection continuum of care sex key population EuropeSexMicrobiology (medical)PopulationSocio-culturale03 medical and health sciencesAcquired immunodeficiency syndrome (AIDS)SDG 3 - Good Health and Well-beingmedicinemedia_common.cataloged_instanceHumansEuropean UnionEuropean unioneducationPandemicsHIV infection ; continuum of care ; sex ; key population ; Europebusiness.industrySARS-CoV-2COVID-19HIVmedicine.diseaseHIV infectioncontinuum of care030112 virologyMajor Articles and CommentariesKey populationAnti-Retroviral Agentbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDemography
researchProduct

Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

2018

AbstractNatural resistance-associated substitutions (RASs) are reported with highly variable prevalence across different HCV genotypes (GTs). Frequency of natural RASs in a large Italian real-life cohort of patients infected with the 4 main HCV-GTs was investigated. NS3, NS5A and NS5B sequences were analysed in 1445 HCV-infected DAA-naïve patients. Sanger-sequencing was performed by home-made protocols on 464 GT1a, 585 GT1b, 92 GT2c, 199 GT3a, 16 GT4a and 99 GT4d samples. Overall, 20.7% (301/1455) of patients showed natural RASs, and the prevalence of multiclass-resistance was 7.3% (29/372 patients analysed). NS3-RASs were particularly common in GT1a and GT1b (45.2-10.8%, respectively), mai…

Male0301 basic medicineSofosbuvirHepacivirusDrug Resistancelcsh:MedicineHepacivirusViral Nonstructural Proteinsmedicine.disease_causeGastroenterologyHepatitis C Virus; HCV resistance-testchemistry.chemical_compound0302 clinical medicineGenotypePrevalenceVirallcsh:ScienceHCV resistance-testMultidisciplinarybiologyHepatitis CMiddle AgedSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCohortHCVFemale030211 gastroenterology & hepatologymedicine.drugAdultmedicine.medical_specialtyHepatitis C VirusGenotypeHCV RASHepatitis C virus03 medical and health sciencesInternal medicineDrug Resistance ViralmedicineHumansAdult; Aged; Drug Resistance Viral; Female; Hepacivirus; Hepatitis C; Humans; Italy; Male; Middle Aged; Prevalence; Viral Nonstructural Proteins; GenotypeNS5ANS5BAgedbusiness.industrylcsh:RHepatitis C Virus HCV resistance-testbiology.organism_classificationmedicine.disease030104 developmental biologychemistrylcsh:Qbusiness
researchProduct

Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry

2021

Abstract Objectives To investigate survival of IL-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. Patients and methods Multicentre retrospective study analysing patients affected by the most common mAID treated with anakinra or canakinumab. Survival curves were analysed with the Kaplan-Meier method. Statistical analysis included a Cox-proportional hazard model to detect factors responsible for drug discontinuation. Results Seventy-eight patients for a total of 102 treatment regimens were enrolled. The mean treatment duration was 29.59 months. The estimated D…

Male0301 basic medicineTime FactorsSettore MED/16 - REUMATOLOGIAInterleukin-1beta0302 clinical medicineSettore MED/38 - Pediatria Generale E SpecialisticaMonoclonalPharmacology (medical)RegistriesHumanizedmedia_commonIL-1 anakinra canakinumab innovative biotechnologies monogenic autoinflammatory disorders personalized medicinepersonalized medicineMiddle AgedPenetranceTreatment OutcomeAnakinraAntirheumatic AgentsAutoinflammationIL-1; anakinra; canakinumab; innovative biotechnologies; monogenic autoinflammatory disorders; personalized medicine; Adult; Antibodies Monoclonal Humanized; Antirheumatic Agents; Female; Follow-Up Studies; Hereditary Autoinflammatory Diseases; Humans; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Male; Middle Aged; Retrospective Studies; Time Factors; Treatment Outcome; Young Adult; RegistriesFemalemedicine.drugAdultDrugmedicine.medical_specialtymedia_common.quotation_subjectAntibodies Monoclonal HumanizedcanakinumabAntibodiesYoung Adult03 medical and health sciencesinnovative biotechnologiesRheumatologyInternal medicinemedicineHumansAdverse effectSurvival analysismonogenic autoinflammatory disordersRetrospective Studies030203 arthritis & rheumatologyAnakinraIL-1business.industryHereditary Autoinflammatory DiseasesRetrospective cohort studyInterleukin 1 Receptor Antagonist ProteinCanakinumab030104 developmental biologyObservational studybusinessFollow-Up Studies
researchProduct

Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

2017

Background & Aims: Despite the excellent efficacy of direct-acting antivirals (DAA) reported in clinical trials, virological failures can occur, often associated with the development of resistance-associated substitutions (RASs). This study aimed to characterize the presence of clinically relevant RASs to all classes in real-life DAA failures. Methods: Of the 200 virological failures that were analyzed in 197 DAA-treated patients, 89 with pegylated-interferon+ribavirin (PegIFN+RBV) and 111 without (HCV-1a/1b/1g/2/3/4=58/83/1/6/24/25; 56.8% treatment experienced; 65.5% cirrhotic) were observed. Sanger sequencing of NS3/NS5A/NS5B was performed by home-made protocols, at failure (N= 200) and w…

Male0301 basic medicinehepatitis C virusSustained Virologic ResponseSofosbuvirHepacivirusDrug ResistanceHepacivirusresistance-associated substitutionsViral Nonstructural ProteinsVARIANTSNS5Amedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRecurrenceINFECTIONantiviral therapyMedicinehepatitis C viruViralTreatment FailureChronicantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; hepatologybiologyGENOTYPE 1virus diseasesMiddle Agedantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutionsSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CItalyCombinationInterferonDrug Therapy CombinationFemale030211 gastroenterology & hepatologyAuthor Keywords:antiviral therapyRIBAVIRINSequence AnalysisHumanmedicine.drugmedicine.medical_specialtyDaclatasvirGenotypeHepatitis C virusAntiviral AgentsLONG-TERM PERSISTENCEDACLATASVIR03 medical and health sciencesDrug Therapyantiviral therapy; direct-acting antivirals; hepatitis C virus; resistance test; resistance-associated substitutions; Aged; Antiviral Agents; Drug Resistance Viral; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Italy; Male; Middle Aged; Mutation; Recurrence; Ribavirin; Sequence Analysis DNA; Sofosbuvir; Sustained Virologic Response; Treatment Failure; Viral Nonstructural Proteins; HepatologyTREATMENT-NAIVEInternal medicineDrug Resistance ViralRibavirinHumansNS5Aresistance testdirect-acting antiviralsAgedAntiviral Agentresistance-associated substitutiondirect-acting antiviralHepaciviruHepatologyresistance test KeyWords Plus:HEPATITIS-C VIRUSbusiness.industryRibavirinViral Nonstructural ProteinSequence Analysis DNADNAHepatitis C ChronicHepatologybiology.organism_classificationClinical trial030104 developmental biologySOFOSBUVIRchemistrySequence AnalysihepatologyMutationImmunologyInterferonsSofosbuvirbusiness
researchProduct

Associations between cognitive performance and the rehabilitation, medical care and social support provided to French children with Prader-Willi synd…

2020

International audience; Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder with a characteristic behavioural phenotype. A multidisciplinary approach to care is required to prevent multiple medical complications in individuals affected by PWS. The aim of this study was to describe the rehabilitation, medical care, educational and social support provided to school-aged French PWS patients with varying neuropsychological profiles. Data were obtained from a French multicentre study that included patients aged 4-20 years with diverse genetic syndromes. Nineteen PWS subjects with a mean age of 9.2 years were included. The mean full-scale intellectual quotient (IQ) was 58 (W…

Male0301 basic medicinemedicine.medical_treatmentIntellectual disabilityMESH: CognitionCBCL030105 genetics & heredityCognitionMultidisciplinary approachMESH: ChildIntellectual disabilityMedicineChildGenetics (clinical)RehabilitationMESH: Hormone Replacement TherapyNeurological RehabilitationNeuropsychologyWechsler Adult Intelligence ScaleGeneral Medicine3. Good healthMESH: Young AdultChild PreschoolEducation SpecialFemaleFrancePrader-Willi SyndromeOccupational therapymedicine.medical_specialtyAdolescentHormone Replacement TherapyMESH: Social Support[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human geneticsYoung Adult03 medical and health sciencesSocial supportMESH: Neurological RehabilitationGeneticsHumansPsychiatryMESH: AdolescentMESH: Humansbusiness.industryMESH: Child PreschoolSocial Supportmedicine.diseaseMESH: MaleMESH: FrancePatient care management030104 developmental biologyMESH: Education Special[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsMESH: Prader-Willi SyndromebusinessMESH: FemaleEuropean Journal of Medical Genetics
researchProduct

Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis

2019

International audience; Objective: Weight loss has been identified as a negative prognostic factor in amyotrophic lateral sclerosis, but there is no evidence regarding whether a high-caloric diet increases survival. Therefore, we sought to evaluate the efficacy of a high-caloric fatty diet (HCFD) for increasing survival.Methods: A 1:1 randomized, placebo-controlled, parallel-group, double-blinded trial (LIPCAL-ALS study) was conducted between February 2015 and September 2018. Patients were followed up at 3, 6, 9, 12, 15, and 18 months after randomization. The study was performed at 12 sites of the clinical and scientific network of German motor neuron disease centers (ALS/MND-NET). Eligible…

Male0301 basic medicinemortality [Amyotrophic Lateral Sclerosis]MESH: Combined Modality Therapy[SDV]Life Sciences [q-bio]law.invention0302 clinical medicineMESH: RiluzoleRandomized controlled triallawdiet therapy [Amyotrophic Lateral Sclerosis]Clinical endpointMedicineMESH: Double-Blind Methodtherapeutic use [Riluzole]MESH: Amyotrophic Lateral Sclerosismethods [Combined Modality Therapy]education.field_of_studyRiluzoleMESH: Middle AgedHazard ratioMESH: Neuroprotective AgentsMiddle Agedtherapeutic use [Neuroprotective Agents]Combined Modality Therapy3. Good healthRiluzole[SDV] Life Sciences [q-bio]Neuroprotective AgentsNeurologyMESH: Survival AnalysisFemalemedicine.drugmortality [Diet High-Fat]medicine.medical_specialtyPopulationDiet High-FatPlacebo03 medical and health sciencesDouble-Blind MethodInternal medicineHumansddc:610educationSurvival analysisMESH: Humansdrug therapy [Amyotrophic Lateral Sclerosis]business.industryAmyotrophic Lateral SclerosisSurvival AnalysisConfidence intervalMESH: MaleMESH: Diet High-Fat030104 developmental biologyNeurology (clinical)businessMESH: Female030217 neurology & neurosurgery
researchProduct

Head-to-head comparison of plasma cTnI concentration values measured with three high-sensitivity methods in a large Italian population of healthy vol…

2019

Abstract Background The study aim is to compare cTnI values measured with three high-sensitivity (hs) methods in apparently healthy volunteers and patients admitted to emergency department (ED) with acute coronary syndrome enrolled in a large multicentre study. Methods Heparinized plasma samples were collected from 1511 apparently healthy subjects from 8 Italian clinical institutions (mean age: 51.5 years, SD: 14.1 years, range: 18–65 years, F/M ratio:0.95). All volunteers denied chronic or acute diseases and had normal values of routine laboratory tests. Moreover, 1322 heparinized plasma sample were also collected by 9 Italian clinical institutions from patients admitted to ED with clinica…

Male0301 basic medicineprincipal component analysisvery elderlyClinical BiochemistryheparinizationBiochemistryPatient Admission0302 clinical medicineReference ValuesLimit of Detectionblood analysisTroponin IHealthy volunteers80 and overMyocardial infarctionAcute coronary syndrome; Cardiac troponins; High-sensitivity methods; Myocardial infarction; Reference population values; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged 80 and over; Blood Chemical Analysis; Female; Humans; Italy; Male; Middle Aged; Myocardium; Patient Admission; Reference Values; Troponin I; Young Adult; Emergency Service Hospital; Healthy Volunteers; Limit of DetectionReference population valuescomparative studyHigh-sensitivity methodsAged 80 and overemergency wardEmergency Servicehospital emergency servicetroponin I acute coronary syndromeSettore BIO/12clinical trialGeneral Medicinecardiac troponin 1 CLIAMiddle AgedHealthy Volunteerspriority journalItaly030220 oncology & carcinogenesisCardiac troponinFemaleAcute coronary syndromeEmergency Service HospitalAdultmedicine.medical_specialtyAcute coronary syndromecardiac muscleAdolescentHead to headheart infarctionArticleYoung AdultHospital03 medical and health sciencesbloodInternal medicinemedicinesexHumanscontrolled studyADVIA Centaurdiagnostic test accuracy studyhumannormal humanproceduresAgedbusiness.industryMyocardiumTroponin IBiochemistry (medical)reference valueEmergency departmentmedicine.diseasemajor clinical studyhospital admissionyoung adult Acute Coronary SyndromeHigh-sensitivity methodMyocardial infarctionmulticenter study030104 developmental biologySettore BIO/12 - Biochimica Clinica E Biologia Molecolare Clinicaageprotein blood levelReference valuesCardiac troponinsbusinessmetabolismBlood Chemical Analysis
researchProduct